The strategic market sector of RDGL is isotope applications.  Currently, the Company is engaged in the development of RadioGel^™, an Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.